Tepmetko (tepotinib)

pCPA File Number: 21997

Negotiation Status:

Concluded with an LOI

Indication(s):

Non-small cell lung cancer (NSCLC), locally advanced unresectable metastatic, harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations, in adult patients

Sponsor/Manufacturer:

EMD Serono Canada, a division of EMD Inc.

CDA-AMC Project Number:

PC0255-000

pCPA Engagement Letter Issued:

2023-03-09

Negotiation Process Concluded:

2023-06-22